Compare Apollo Global Management Ord Shs (APO) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Apollo Global Management Ord Shs vs Cassava Sciences Inc — how do they compare? Apollo Global Management Ord Shs trades at $120 (market cap $69.38B), while Cassava Sciences Inc trades at $1.18 (market cap $57.49M). The key difference: Apollo Global Management Ord Shs is far larger — about 1206.8× Cassava Sciences Inc's market cap, and Apollo Global Management Ord Shs pays a 1.87% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| APO | FLNA | |
|---|---|---|
Market Cap | $69.38B | $57.49M |
Sector | Financials | Health |
52-Week High | $156.05 | $4.64 |
52-Week Low | $100.30 | $1.16 |
Enterprise Value | -$168.19B | -$29.09M |
Dividend Yield | 1.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Apollo Global Management (APO) trades at $120.34, up 0.42% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 EPS of $1.94, beating estimates, and maintains strong analyst support with 23 buy ratings. Recent news highlights private credit growth opportunities alongside liquidity concerns in Apollo's funds.
APO's outlook is supported by earnings beats and a $149.86 consensus price target, but risks include private credit liquidity pressures and a high P/E ratio of 75.69. Investor sentiment is mixed due to ongoing fund withdrawal caps and legal investigations, though long-term growth in alternative assets remains a positive catalyst.
FLNA trades at $1.18, down 0.84% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -79.59% and ROA at -62.5%, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights Q1 2026 financial results and scientific presentations on TSC-related epilepsy therapies. Analyst consensus remains positive with 67% buy ratings.
While analyst sentiment is bullish, FLNA faces significant fundamental challenges with negative cash flow and earnings. The primary investment opportunity lies in successful drug development, but risks include sustained cash burn and clinical trial outcomes. Investors should weigh the high-risk biotech profile against potential pipeline catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apollo Global Management Ord Shs
Apollo Global Management Inc is an alternative investment manager. It serves various sectors such as chemicals, manufacturing and industrial, natural resources, consumer and retail, consumer services, business services, financial services, leisure, and media and telecom and technology. The company operates in three business segments that are Private Equity, Credit, and Real Assets. It generates maximum revenue from the Credit segment in the form of fees. The credit segment primarily invests in non-control corporate and structured debt instruments including performing, stressed and distressed instruments across the capital structure. It also includes Corporate Credit
Read more on APO →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
